U lcerative colitis (UC) is a chronic inflammatory disorder of the colon of unknown etiology. The prevalence ranges from 188 to 240 per 100,000 persons. 1 The initial presentation of the disease is variable as is the subsequent course, which can range from inactive disease to medically refractive fulminant colitis requiring urgent colectomy. 2 The aim of therapy for UC is to induce and maintain remission. In a subset of patients, this can be achieved by the use of 5-aminosalicylic acid (5-ASA) compounds, which are the first line of therapy for mild-to-moderate disease 3 ; however, some patients require corticosteroids (CS) to induce remission. 4, 5 Unlike Crohn's disease, in which different prognostic indicators can be used to assess the course of the disease, 6, 7 there are less well-established markers in UC. Several studies have identified CS use as a poor prognostic indicator. [8] [9] [10] [11] [12] It has been suggested that CS use identifies a group of patients who will have a more aggressive disease course. [8] [9] [10] [11] [12] A study by Faubion et al 9 on the natural history of inflammatory bowel disease after CS use demonstrated that among patients with UC who required CS therapy, 22% patients had steroid dependency and 29% patients had colectomy over the course of 1 year after starting CS.
In the view of more aggressive disease course in those patients who require CS therapy, it would be clinically useful to identify factors that can predict the need for CS therapy over the course of the disease. Our aim was to develop a prediction model that could be used at the time of UC diagnosis to estimate the need for CS therapy over the course of the disease. This model would incorporate variables that are readily available at the time of UC diagnosis. To achieve this goal, we used a previously validated nationwide inception cohort of patients with UC 11, 13 from the Veterans Affairs (VA) Database. The VA is the largest integrated health care system in the United States serving approximately 8.3 million veterans per year. 14 
METHODS

Data Source
Nationwide data were obtained from the VA Pharmacy Benefits Management and Corporate Data Warehouse databases. This data source allows automated data extractions to collect information regarding patients' demographics, pharmacy records, laboratory findings, and procedures. Individual patient records were collected through VA electronic record system. (Compensation and Pension Record Interchange [CAPRI]).
Study Population
We used a previously validated cohort of newly diagnosed patients with UC to conduct this study. 11, 13 Veterans who were seen and followed in the VA health care system from October 1, 2001 to October 1, 2011 were identified using International Classification of Diseases, Ninth Revision (ICD-9) codes for UC (556.xx). Newly diagnosed patients with UC were followed up from the date of UC diagnosis until the earliest of the following event: undergoing a colectomy, lost to follow-up in the VA system, deceased, and end of the observational period (October 2015).
Inclusion and Exclusion Criteria
All patients included in our study were required to have (1) at least 4 UC ICD-9 codes in the VA database and three 5-ASA prescriptions, (2) at least 20 encounters with the VA before the date of the first evidence of UC, (3) an initial UC diagnosis after October 2001, and (4) a documented index endoscopy in the VA system within 6 months of the first evidence UC. In addition, we excluded patients who underwent colectomy during the first attack of UC and those who develop feature of Crohn's disease or indeterminate colitis over the course of the follow-up. After initial screening, all charts were individually reviewed by 2 investigators to confirm the diagnosis of UC and ensure all the relevant data were present.
The purpose behind requirement of .20 encounters within VA system was to allow enough exposure to the health care provider after which any history of UC should have been recorded; furthermore, this helped ensure good adherence of the patients in seeking health care through the VA system and, subsequently, increased the validity of our outcome detection.
Predictors
Candidate variables included all demographics (age, sex, and race), disease-related factors such as laboratory results (e.g., serum albumin level), and the presence of iron-deficiency anemia (IDA) at the time of UC diagnosis and index colonoscopy findings (i.e., UC extent and severity) that are plausibly linked with CS therapy use in the future and are routinely available at the time of or shortly after UC diagnosis.
Outcome
Our outcome was CS utilization over the course of the disease from the time of UC diagnosis. CS use was defined as at least 1 course of oral or intravenous prednisone for the management of UC.
Data Collection
The records of the patients identified in this cohort were manually reviewed by 2 investigators to collect the data on oral prednisone prescriptions dispensed for only UC management over the follow-up period. Prednisone data elements that were collected included dispense date and stop dates, refill dates. Other data collected by manual chart review included patients' demographics at the time of UC diagnosis, age, sex, race (i.e., white, African American, Hispanics, others, and unknown), serum albumin (g/dL) level, and the presence of IDA at the time of UC diagnosis. IDA at the time of UC diagnosis was defined as a ferritin level ,100 mg/L and transferrin saturation ,16% in patients with anemia or combination of both. 15 Hypoalbuminemia at the time of UC diagnosis was defined as albumin level ,3.5 g/dL. Additional information extracted for each patient at the time of UC diagnosis included extent and severity of disease at index colonoscopy. The extent of UC at index endoscopy was assessed using Montreal classification (E0 ¼ no involvement, E1 ¼ proctitis, E2 ¼ left-sided disease till splenic flexure, and E3 ¼ right sided disease or pancolitis). 16 The severity of UC at the time of index endoscopy was assessed using criteria established by Froslie et al 17 (F0 ¼ normal mucosa, F1 ¼ light erythema or granularity, and F2 ¼ granularity, friability, and bleeding, with or without the addition of ulcerations).
Ethical Consideration
This study was approved by Philadelphia VA Medical Center Institutional Review Board committee.
Statistical Analysis
The entire eligible study cohort was randomly divided in a 2:1 ratio to generate a test and validation set. The associations between each candidate predictor and the outcomes were evaluated using a univariate logistic regression analysis to estimate odds ratios and 95% confidence intervals (CIs). All variables associated with a P value ,0.25 in the univariate analysis were further evaluated in a multivariate model. We had complete data for all variables except for baseline albumin level and/or iron study results which were missing in 137 (16%) of the patients. Given the relatively small amount of missing data, we chose to perform complete case analyses in all models. In the multivariate logistic regression model, we used backward elimination for variable selection with P values of ,0.001 and .0.05 as inclusion and exclusion criteria, respectively. Because there was substantial collinearity between baseline UC extent and UC severity, we developed separate prediction models including one of these at a time. In addition, we repeated the multivariate model after testing continuous variables for linearity and correction using fractional polynomials of second degree with powers 22, 21, 20.5, 0, 0.5, 1, 2, and 3 to improve the fit of the models.
The models were tested for colinearity (variance inflation factor .10) and 2-way interactions. The calibration of each of the models was evaluated using the Hosmer-Lemeshow goodness-offit test with P value .0.05 indicating adequately fit of the logistic function and values .0.2 indicating extremely good model fits. The discrimination ability of the models was calculated using the area under the receiver operator curve.
The analysis was repeated in the validation set of the data. All analyses were performed using STATA 14 (Stata Corp., College Station, TX).
RESULTS
We included 836 patients newly diagnosed with UC in the VA system between 2001 and 2011 ( Fig. 1 ) and followed till October 2015. Of the 836 patients, 137 patients were excluded from the complete case analysis because of missing information on serum albumin or iron studies to determine the cause of anemia at UC diagnosis. Table 1 presents the distribution of relevant characteristics of the entire cohort. The eventual complete case analysis included a total of 699 patients with UC, with 465 (66.5%) in the development cohort and 234 (33.5%) in the validation cohort. A total of 288 patients (41.2%) required CS use during the follow-up period.
Prediction of CS Use Based on UC Extent at Diagnosis
In the development cohort, the candidate predictors that remained after the univariate analysis and backward elimination included age at the time of UC diagnosis, presence of hypoalbuminemia at the time of UC diagnosis, presence of IDA at the time of UC diagnosis, African American ethnicity, UC extent level E2 (left-sided colitis), and UC extent level E3 (pancolitis/right-sided colitis) at UC diagnosis. The area under the receiver operator curve for the multivariable model based on these predictors was 0.71 (95% CI, 0.66-0.76) ( Fig. 2A) , with a Hosmer-Lemeshow goodness-of-fit test P value of 0.44.
In the validation cohort, the model had similar performance in terms of discrimination and calibration ( Table 2) .
Prediction of CS Use Based on UC Severity at Diagnosis
In the development cohort, the candidate variables that remained in the model included age at UC diagnosis, presence of hypoalbuminemia at UC diagnosis, presence of IDA at UC diagnosis, African American ethnicity, UC severity level F2 (friability or ulceration or bleeding or granulation) at UC diagnosis. The model including these predictors had good (Fig. 2B) with Hosmer-Lemeshow goodness-of-fit test P value of 0.73, indicating satisfactory calibration. In the validation cohort, the model preformed similarly well ( Table 2) . The full models for both outcomes including the intercept are presented in Table 3 . The predicted probability of the outcome can be evaluated from any combination of predictor values. The predicted probability of the outcome event is as follows:
where b j is the regression coefficient for predictor X j , and b 0 is the model intercept.
With an aim to simplify the calculation involved in the model, we developed web-based software incorporating all the predictive factors. (Fig. 3A, B) This software can also be developed into a mobile application.
DISCUSSION
Requirement of CS therapy for disease management has been recognized as a poor prognostic marker among patients with UC. [8] [9] [10] [11] [12] Using a large nationwide population-based cohort, we found that younger age at UC diagnosis, non-African American ethnicity, lower serum albumin level, presence of IDA at UC diagnosis, pancolitis, and increased severity of endoscopic disease activity at index colonoscopy predict a higher chance of CS use in the course of the disease. Some of these markers have been previously identified individually to have prognostic significance but for the first time we have combined all these indicators to produce a formula that is easily reproducible and provides a quantitative estimate of the overall risk of CS use.
While developing a prediction model, we used elements that are readily available at the time of diagnosis. In an effort to make our prediction model more user-friendly, we developed web-based software in which we incorporated the abovementioned individual factors. The software program was based on the prediction model incorporating the extent of UC at initial diagnosis as it is a more objective finding than severity of UC. This obviates the need for a scientific calculator and the individual predictive factors can be individually entered to instantly generate a quantitative value. As an example of its use, a non-African American patient who was 60 years of age at UC diagnosis, with hypoalbuminemia and IDA at the time of UC diagnosis and had E3 extent of UC at diagnosis, the predicted probability of CS use can be calculated to be 81.25%. (Fig. 3A) Another patient who was 30 years of age at UC diagnosis, with African American race, without hypoalbuminemia and IDA at the time of UC diagnosis, and had E1 extent at diagnosis, the predicted probability of CS use can be calculated to be 13.56% (Fig. 3B) .
CS are the mainstay of therapy for the initial medical management of moderate-to-severe UC. 18 Multiple population-based studies focusing on natural history of UC showed that rates of CS use range from 34% to 63% over a variable period of follow-up ranging from 1 year to 7 years. [8] [9] [10] [11] 19, 20 CS use identifies a more aggressive phenotype of the disease and is a marker of poor prognosis, defined by higher chances of steroid dependency and colectomy for management of UC. [8] [9] [10] [11] [12] CS dependency rate among UC patients with previous CS exposure was 22%, 38%, 42%, and 68% over the median follow-up period of 1 year, 3.4, 6.9, and 5 years respectively. [9] [10] [11] The requirement of colectomy among patients who had previous CS exposure ranged from 2% to 29% over the median follow-up period of 1 year to 3.4 years. [8] [9] [10] [11] 20 Apart from predicting adverse outcomes in UC, CS therapy inherently is associated with drug-related short-term and longterm side effects. Short-term side effects of CS therapy include infection, ecchymosis, fluid retention, hypertension, hyperglycemia, and psychiatric illness. 3, [21] [22] [23] Long-term side effects include decreased bone mineral density, glaucoma, cataracts, adrenal b values are expressed per 1-unit increase for continuous variables and for the condition present in dichotomous variables. The predicted probability of the outcome can be evaluated from any combination of predictor values. The predicted probability of the outcome event is as follows: insufficiency, impaired wound healings, new-onset diabetes mellitus, and higher mortality. 3, [21] [22] [23] [24] In the view of adverse disease prognosis associated with CS therapy and inherent side effects of CS use, it is clinically useful for the physician to have a tool at the time of UC diagnosis to identify patients at high risk for CS requirement over the course of the disease. Patients with the above-mentioned key predictors of CS use may be a potential target for a higher dose of 5-ASA at disease onset which may prevent further relapses, and eventually decrease the chance of CS use. However, no trials have specifically looked at 5-ASA dosing based on risk-stratification at the time of UC diagnosis to induce remission and prevent relapses in the future. This is an area of further research. However, in the absence of such data, a meta-analysis by Ford et al 25 on the use of 5-ASA in patients with UC showed that higher dose of 5-ASA in quiescent UC seems to reduce the risk of disease relapse than lower dose of 5-ASA. (Relative risk of relapse ¼ 0.79; 95% CI, 0.64-0.97, P value 0.02). Also, those patients who have a higher risk for steroid use might be considered as appropriate for combined topical and oral 5-ASA therapy in an effort to avoid future CS use.
Adherence to medications has been identified as the key factor in maintaining disease remission in UC. A study by Kane et al 26 showed that nonadherence to a prescribed regimen of 5-ASA dramatically increased the risk of symptomatic relapse (61% versus 11%, P value 0.001). A study by Hawthorne et al 27 showed that a combination of educational and behavioral strategies tailored to individual patient optimized 5-ASA adherence in patients with UC. Giving a numerical value to the risk of using CS will give patients a better insight into the course of their disease. It is hoped that this will lead to improved patient-physician discussion of the disease course, which in turn leads to improved medication compliance and decreased flare rates in the future. Also, patients who have a high risk of CS use may benefit from more frequent monitoring through clinical follow-up and evaluation of biomarkers.
There are certain limitations in our study. In using the VA database, we had to conduct a retrospective study which has its own inherent limitations. We are subject to data entry errors, and there is also heterogeneity of care across the 170 sites. Certain aspects of disease may not be recorded and tests which are considered standard of care may not be performed. The VA population is predominately composed of males, which could potentially limit the generalizability of the findings to females. However, none of the previous studies has shown that sex plays a role in the prognosis of UC. Because we used the VA pharmacy database to estimate CS exposure rates, prescriptions filled outside the VA were not captured by our analysis. We anticipate the magnitude of such misclassification to be negligible as previous reports have shown that veterans have very good adherence in using the VA pharmacy. [28] [29] [30] Furthermore, all veterans included in this study had to have more than 20 visits before UC to ensure adherence to the VA system.
The strength of this study was based on the broad scope of patients included and on the nationwide data rather than data from tertiary centers, in which there is a likelihood of referral bias. We had patients from 170 sites spanning 48 states including Puerto Rico. To our knowledge, this is the largest cohort of patients with UC and the first multicenter nationwide study conducted in the United States. Patients were followed for the median observation period of 8 years to identify CS use after their UC diagnosis. The strength of our prediction model lies in the ease of its use. It uses parameters that are checked by both gastroenterologists as well as primary care physicians and can be readily incorporated in their practice. In addition, we developed the first user-friendly webbased software which can be easily incorporated into a mobile application facilitating ease of use.
In conclusion, we developed a web-based prediction model that demonstrated excellent performance in predicting CS use in newly diagnosed patients with UC. This tool can be easily incorporated into clinical practice because it used parameters that are readily available at the time of UC diagnosis, such as younger age, African American ethnicity, albumin level, presence of IDA, and extent and severity of disease on index colonoscopy. Such a model, once externally validated, could be used by clinician to identify patients with poor disease prognosis who may require closer follow-up.
